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LATE-ONSET NEONATAL SEPSIS CAUSED BY GROUP A STREPTOCOCCUS 
- AN UNLIKELY AGENT
SÉPSIS NEONATAL TARDIA A STREPTOCOCCUS DO GRUPO A - UM AGENTE IMPROVÁVEL
ABSTRACT






Group A Streptococcus is an uncommon neonatal sepsis agent. Transmission in the community through a carrier should be considered. This 
case	highlights	the	importance	of	infection	preventive	measures	for	the	newborn	at	home.	













Nascer e Crescer - Birth and Growth Medical Journal 
2019;28(1):	26-29.	doi:10.25753/BirthGrowthMJ.v28.i1.14558
NASCER E CRESCER
BIRTH AND GROWTH MEDICAL JOURNAL




When	 occurring	 after	 72	 hours	 of	 life,	 it	 is	 defined	 as	 late-onset	
neonatal sepsis (LOS). LOS has been well studied both in premature 
and	 hospitalized	 neonates.	 Immaturity,	 invasive	 interventions,	
failure	 of	 early	 breastfeeding,	 prolonged	 parenteral	 nutrition,	
and	 hospitalization	 are	 known	 risk	 factors.1-2 While early-onset 
neonatal	sepsis	(EOS)	is	usually	associated	with	vertical	transmission,	
microbiology	 of	 LOS	 can	 reflect	 the	 nosocomial	 or	 community	
environment, with the highest incidence observed between ten and 
22 days of life.1
The	 causative	 pathogens	 of	 LOS	 vary	 geographically	 and	 differ	
from	EOS.	Coagulase-negative	Staphylococcus	are	the	predominant	
pathogens	of	hospital-acquired	LOS	in	industrialized	countries,	while	
Escherichia coli and group B Streptococcus are the main agents of 
community-acquired	LOS.1-3
With	 the	 advent	 of	 antibiotics,	 neonatal	 sepsis	 caused	 by	 Group	
A	Streptococcus	(GAS)	became	rare,	but	a	high	mortality	rate	is	still	
observed.4-5	According	to	the	World	Health	Organization,	 incidence	
of neonatal GAS bacteremia is 0.55 per 1000 live births.6 
Neonatal	sepsis	has	nonspecific	clinical	signs	and	symptoms,	such	
as	 grunting,	 temperature	 instability,	 respiratory	 distress,	 apnea,	
jaundice,	 feeding	 intolerance,	bulging	fontanelle,	seizures,	and	skin	
lesions.7 
The	 spectrum	 of	 clinical	 presentations	 of	 invasive	 GAS	 infections	




A	 14-day-old	 female	 neonate	 was	 taken	 to	 the	 Emergency	
Department	due	to	feeding	refusal	and	hyporeactivity	since	the	day	
before. She did not have a fever. 
Pregnancy	 was	 unremarkable	 and	 the	 female	 infant	 was	 born	
by	 normal	 delivery	 at	 36	 weeks	 of	 gestation,	 three	 hours	 after	
spontaneous membrane rupture. Group B streptococcus screening 
was not performed. The newborn was discharged on the third day 
of life. 
On arrival to the emergency room, the newborn was hypotonic, 
with	 a	 weak	 cry,	 pallor,	 and	 signs	 of	 dehydration	 (dry	 mucous	
membranes, depressed anterior fontanelle, and weight loss). She was 
hemodynamically stable, without respiratory distress or groaning. 
There	was	no	skin	rash	or	signs	of	cutaneous	inflammation.	
Blood	 samples	 revealed	 a	 leukocyte	 count	 of	 18.100/mm3,	 with	
81%	neutrophils;	platelet	count	of	28.7000/mm3;	C-reactive	protein	






Sepsis	 was	 the	 main	 differential	 diagnosis	 and	 intravenous	
cefotaxime,	 ampicillin,	 and	fluid	 therapy	were	 started.	 The	patient	
had	a	good	clinical	evolution,	with	no	hemodynamic	or	respiratory	
instability, and no fever or cutaneous signs. 
A	 multisensitive	 GAS	 (emm	 type	 STG7882)	 was	 isolated	 in	 the	
blood culture and ten-day treatment with ampicillin was completed. 
Cerebrospinal	fluid	and	urine	cultures	were	negative.	
All	 six	 co-inhabitants	were	 investigated	 for	 oropharynx	GAS.	 GAS	
antigen	positivity	was	only	 reported	 in	a	 two-year	old	cousin	 (who	
presented	 amygdalin	 hypertrophy	 without	 hyperemia	 or	 exudates	
and no fever), who was treated.
DISCUSSION
 
GAS	 is	 an	 uncommon	 cause	 of	 neonatal	 sepsis.	 A	 nonspecific	
clinical	presentation	 (hypotonia,	weak	cry,	pallor,	and	dehydration)	
was	 observed	 in	 this	 case.	 Fever	 was	 not	 present	 in	 this	 patient,	
although it is a common sign in LOS associated with GAS and may 
reflect	the	neonate’s	inability	to	respond	to	the	pathogen.4 No typical 
rash	or	local	soft	tissue	infection	signs	suggesting	GAS	infection	were	
observed,	namely	 impetigo,	 cellulitis,	omphalitis,	or	paronychia.4,8,9 
Other	 focal	 infections	 −	 as	 pneumonia	 and	 meningitis	 −	 were	
excluded.	
Pathophysiology of LOS due to GAS is poorly understood and 
does not seem to be related to perinatal factors. Transmission 
in the community through a carrier, usually the mother, should 




unnecessary	 use	 of	 antibiotics.10	 The	 index	 case	 was	 potentially	
a	 two-year-old	 cousin	 of	 the	 neonate,	 who	 was	 identified	 as	 an	
asymptomatic	 carrier.	 The	 prevalence	 of	 GAS	 carrier	 status	 in	
children	is	12%,	varying	with	age.	Carriers’	screening	and	treatment	
is	 recommended	 in	 some	 situations,	 such	 as	outbreaks	of	 invasive	
GAS disease.11	Although	molecular	confirmatory	study	of	the	 index	
case was not been performed, the carrier was treated to prevent 
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reinfection	of	the	neonate.
The	high	 rate	of	 community-acquired	 resistant	 sepsis	 is	 a	 serious	
global	 public	 health	 concern,	 supporting	 empirical	 treatment	with	
cefotaxime	 and	 ampicillin.12	 For	 GAS	 infections,	 benzylpenicillin	
remains	 the	 antibiotic	 of	 choice,	 as	 resistance	 has	 not	 been	
described.	Alternatively,	ampicillin	may	be	used,	as	all	GAS	reported	
are	susceptible	to	both	antibiotics.	GAS	has	a	high	rate	of	resistance	
to gentamicin and increasing erythromycin resistance in some 
countries. Clindamycin-resistant strains are mainly associated with 
multi-resistant	clones.	13-15
Several	virulence	factors	contribute	to	the	pathogenic	complexity	of	
GAS. One of the most important is M protein encoded by the emm 
gene. To date, more than 200 emm types and subtypes have been 
identified,	 which	 vary	 according	 to	 geographic	 location.15 Certain 
emm	 types	 are	 associated	 with	 specific	 manifestations,	 but	 few	
studies	 exist	 in	 pediatric	 populations.	 In	 Europe,	 emm	 types	 1,	 3,	
4, 12, and 28 are the most prevalent in children.16 The emm type 
observed in this case (STG7882) is rare, and it can also be found in 
group	G	Streptococcus,	supporting	the	interspecies	genetic	transfer	
of emm alleles.17,18 Recently, Seale et al described a case of invasive 
neonatal disease in Kenya with this emm type, with cutaneous and 
subcutaneous signs.14 Although molecular biology typing is possible, 
more	studies	are	required	to	define	its	role	in	clinical	practice.	
This	case	highlights	the	importance	of	infection	preventive	measures	
directed	 at	 the	 newborn	 at	 home.	 In	 addition	 to	 basic	 hygiene	
measures,	hand	wash	before	picking	up	the	baby	should	be	routine,	
contact	with	poorly	healthy	persons	should	be	restricted,	and	kissing	
the baby's face should be avoided to prevent contagion.19,20
Take-home	messages:
•	 LOS caused by GAS is rare.
•	 Symptoms	 are	 usually	 nonspecific,	 but	 presence	 of	 soft	
tissue	infection	or	toxic	shock-like	syndrome	should	make	the	
clinician consider this agent.
•	 Rapid	GAS	antigen	detection	test	can	be	used	to	determine	the	
index	case	and	avoid	reinfection.
•	 Penicillin/ampicillin	 are	 the	 antibiotics	 of	 choice,	 since	
associated resistance has not be described.
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